摘要
贫血是慢性肾脏病(CKD)尤其是维持性血液透析CKD患者常见并发症,既往主要认为与患者红细胞生成不足及损失过多有关,常使用红细胞生成刺激剂进行治疗。近年来随着研究不断深入,骨矿物质代谢异常、甲状腺功能异常等新的发病机制逐渐被发现,且随着罗沙司他、恩那度司他等新药物的研发和应用,CKD维持性血液透析相关贫血的诊疗形势所有改善。文章就CKD维持性血液透析相关贫血特点及治疗方法展开综述,以期为该病的治疗提供新的思路。
Anemia is a common complication of chronic kidney disease(CKD),especially in CKD patients with maintenance hemodialysis.In the past,anemia was mainly thought to be related to insufficient erythropoiesis and excessive loss in patients,therefore erythropoiesis stimulators were often used for treatment.In recent years,with the deepening of research,new pathogenesis such as abnormal bone mineral metabolism and abnormal thyroid function have been gradually discovered,and with the development and application of new drugs such as roxadustat and enarodustat,the diagnosis and treatment situation of CKD maintenance hemodialysis-related anemia has been improved.The study reviews the characteristics and treatment methods of CKD maintenance hemodialysis-related anemia in order to provide new ideas for the treatment of the disease.
作者
万正红(综述)
周莉(审校)
Wan Zhenghong;Zhou Li(Department of Nephrology/Hemodialysis Room,West China Hospital,Sichuan University,Sichuan Province,Chengdu 610041,China)
出处
《疑难病杂志》
CAS
2024年第12期1515-1518,共4页
Chinese Journal of Difficult and Complicated Cases
基金
四川大学研究生教育教学改革研究项目(GSSCU2021135)。
关键词
慢性肾脏病
维持性血液透析
贫血
治疗
Chronic kidney disease
Maintenance hemodialysis
Anemia
Treatment
作者简介
通信作者:周莉,E-mail:446125447@qq.com。
